Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL
MAb’s CAR-T Like Efficacy Seen Giving Wide Adoption
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
